To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Stopped The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in 20 months

Conditions

• Metastatic Breast Cancer

Interventions

• DRUG: Pegylated liposomal doxorubicin
• DRUG: Capecitabine

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

• [object Object]